Online citations, reference lists, and bibliographies.
← Back to Search

Stabilization Of Recombinant Human Growth Hormone Against Emulsification-induced Aggregation By Pluronic Surfactants During Microencapsulation.

Gang Wei, L. F. Lu, W. Lu
Published 2007 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Protein aggregation upon exposing to the water/organic solvent interface is one of the most significant obstacles in developing poly(lactic-co-glycolic acid) (PLGA) microspheres with double emulsion process. The aim of present study is to devise a formulation strategy to prevent recombinant human growth hormone (rhGH) from aggregation during microencapsulation. The excipients used for stabilizing rhGH were selected from sugars, nonionic surfactants, polyol, and protein. Among the candidates, surfactants exhibited potentialities in protecting rhGH against emulsification-induced aggregation. It was also found that Pluronic F127 showed an outstanding as well as concentration-dependent stabilizing effect on rhGH, which was different to Pluronic F68 and Tween 20. After the rhGH solution comprising F127 and sucrose was emulsified with methylene chloride, the recovery of monomeric protein achieved 99.0%, principally attributed to the presence of F127. This solution was subsequently encapsulated as inner aqueous phase in the PLGA microspheres by a conventional double emulsion process, with the encapsulation efficiency higher than 98%. Improvement in the release of rhGH was observed for the microspheres co-encapsulating Pluronic F127 regardless in the presence or absence of sucrose, compared to the microspheres containing rhGH alone. The result further implied that co-encapsulation of Pluronic F127 in the microspheres played an important role in the stabilization of rhGH.
This paper references
10.1002/(SICI)1097-0290(19991220)65:6<659::AID-BIT6>3.0.CO;2-9
Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism.
H. Kim (1999)
10.1016/S0168-3659(00)00277-7
The effect of a water/organic solvent interface on the structural stability of lysozyme.
M. van de Weert (2000)
10.1021/JS9900654
Protein behavior at the water/methylene chloride interface.
H. Sah (1999)
10.1016/S0168-3659(02)00494-7
Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique.
Shigeyuki Takada (2003)
10.1016/S0168-3659(00)00315-1
Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres.
G. Rosa (2000)
10.1081/PDT-100101400
Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems.
J. A. Schrier (1999)
10.1023/A:1011998615267
Improving Stability and Release Kinetics of Microencapsulated Tetanus Toxoid by Co-Encapsulation of Additives
P. Johansen (2004)
10.1016/S0168-3659(02)00009-3
Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery.
A. Kabanov (2002)
10.1016/S0168-3659(97)00075-8
Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect
J. Cleland (1997)
10.1211/0022357011776667
Improved activity and stability of lysozyme at the water/CH2CI2 interface: enzyme unfolding and aggregation and its prevention by polyols
C. Pérez (2001)
10.1016/S0168-3659(03)00194-9
Biodegradable microspheres for protein delivery.
V. Sinha (2003)
10.1023/A:1016063109373
Stable Formulations of Recombinant Human Growth Hormone and Interferon-γ for Microencapsulation in Biodegradable Mircospheres
J. Cleland (2004)
10.1016/S0168-3659(96)01496-4
Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy
Limor Chen (1997)
10.1023/A:1014818118224
Why Does PEG 400 Co-Encapsulation Improve NGF Stability and Release from PLGA Biodegradable Microspheres?
J. Péan (2004)
10.1016/S0168-3659(98)00148-5
Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation.
H. Sah (1999)
10.1023/A:1020354809581
On Technological and Immunological Benefits of Multivalent Single-Injection Microsphere Vaccines
G. Boehm (2004)
10.1016/S0939-6411(98)00011-3
Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
D. Blanco (1998)
10.1023/A:1012142204132
The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres
O. Johnson (2004)
10.3109/10837459709022619
Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses.
M. Katakam (1997)
10.1016/S0169-409X(97)00050-1
One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate.
Okada (1997)
10.1016/S0378-5173(01)00852-3
Microencapsulation of dissociable human growth hormone aggregates within poly(D,L-lactic-co-glycolic acid) microparticles for sustained release.
H. K. Kim (2001)
10.1016/S0168-3659(01)00511-9
Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation.
I. Genta (2001)
10.1021/JS980175V
Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions.
N. Bam (1998)
10.1023/A:1026498209874
Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles
M. van de Weert (2004)
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.
J. Cleland (1993)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I1.20
Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems.
S. Schwendeman (2002)
10.1002/JPS.2600840609
Effect of surfactants on the physical stability of recombinant human growth hormone.
M. Katakam (1995)
10.1021/JS960480L
Factors affecting the in vitro release of recombinant human interferon‐γ (rhIFN‐γ) from PLGA microspheres
J. Yang (1997)
10.1016/S0939-6411(96)00017-3
Microencapsulation of rh-erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients
M. Morlock (1997)
10.1021/JS980069T
Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone.
H. Costantino (1998)
10.1016/S0378-5173(99)00178-7
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
A. Sánchez (1999)



This paper is referenced by
10.1002/9780470769829.CH4
External Factors Affecting Protein Aggregation
Wei Wang (2010)
10.1517/17425240802680169
Current approaches to stabilising and analysing proteins during microencapsulation in PLGA
C. F. van der Walle (2009)
10.1080/10837450.2018.1502316
Preparation and in vivo pharmacokinetics of rhGH-loaded PLGA microspheres
Zhiying Yu (2019)
Use of excipients to control aggregation in peptide and protein formulations
E. Maggio (2010)
10.1038/s41598-018-28092-8
mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human Growth Hormone (rhGH)
R. Ghasemi (2018)
10.1039/c3nr00474k
Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane.
Eung-Sam Kim (2013)
10.1201/B19038-51
Emulsion-Solvent System for Drug Delivery
Wasfy M. Obeidat (2015)
10.11606/T.87.2010.tde-30092010-102942
Encapsulação das proteínas do veneno de abelha em microesferas de PLGA (Poliéster de Ácido Láctico-Co-Glicólico) para imunoterapia.
R. A. Trindade (2010)
10.1002/9780470769829.CH8
Approaches to Managing Protein Aggregation in Product Development
Wei Wang (2010)
10.1016/J.IJPHARM.2007.10.016
Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation.
Sibao Chen (2008)
10.3109/02652048.2010.489974
Controlled release of bioactive recombinant human growth hormone from PLGA microparticles
M. Rafi (2010)
10.1016/j.ejps.2010.09.008
PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Yolanda Parajó (2010)
10.1021/bm300826v
Thermosensitive nanoparticles with pH-triggered degradation and release of anti-inflammatory cell-penetrating peptides.
Rush L. Bartlett (2012)
10.1201/B19038
Handbook of Encapsulation and Controlled Release
M. Mishra (2015)
EFFECT OF POLYSORBATE-80 CONCENTRATION ON G-CSF FORMULATION USING LIQUID CHROMATOGRAPHY
Amand Bhaskar (2014)
10.1016/j.colsurfb.2019.01.039
Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?
Katia P. Seremeta (2019)
10.1111/j.1749-6632.2012.06681.x
Thymosin β4 sustained release from poly(lactide‐co‐glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia
Jeffrey E. Thatcher (2012)
10.1016/j.ijpharm.2011.02.013
Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination.
R. Osman (2011)
10.3390/ma2030765
Hoffmeister Series Ions Protect Diphtheria Toxoid from Structural Damages at Solvent/Water Interface
J. A. Namur (2009)
Polysorbates, peroxides, protein aggregation, and immuno- genicity - a growing concern.
E. Maggio (2012)
Aggregation of therapeutic proteins
Wei Wang (2010)
10.1080/03639045.2019.1628770
A review on parenteral delivery of peptides and proteins
Divisha Jain (2019)
10.1248/CPB.57.1050
Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders.
Yusuke Tanaka (2009)
10.1007/s11095-013-1014-7
Spray-Dried Chitosan Microparticles for Cellular Delivery of an Antigenic Protein: Physico-chemical Properties and Cellular Uptake by Dendritic Cells and Macrophages
C. Kusonwiriyawong (2013)
The effects of technical and compositional variables on the size and release profile of bovine serum albumin from PLGA based particulate systems
B. Taghipour (2014)
10.3109/08982104.2010.491072
Diphtheria toxoid conformation in the context of its nanoencapsulation within liposomal particles sandwiched by chitosan
Vanessa C. Rescia (2011)
Development of Poly(Lactide-Co-Glycolide) Microspheres for Controlled Release of Thymosin Beta-4 in the Heart
Jeffrey E. Thatcher (2012)
10.3109/10837450.2014.882940
PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches
S. Mohammadi-Samani (2015)
10.1517/17425240903199143
Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients
L. Jorgensen (2009)
10.1016/j.ejps.2013.05.004
Compare and contrast the effects of surfactants (PluronicF-127 and CremophorEL) and sugars (β-cyclodextrin and inulin) on properties of spray dried and crystallised lysozyme.
R. Haj-Ahmad (2013)
10.1016/j.ejps.2016.11.014
Ectoine and hydroxyectoine inhibit thermal‐induced aggregation and increase thermostability of recombinant human interferon Alfa2b
Faranak Salmannejad (2017)
Semantic Scholar Logo Some data provided by SemanticScholar